The immunoscore proposed by Galon et al. predicts early-stage recurrence risk by quantifying the host CD3+ and CD8+ T cell response in the tumor interior (TI) and invasive margin (IM) [3] and is associated with prognosis and combined immunotherapy efficacy [4,5]. This evidence concerns the gene CD8A and neoplasm.